LeonaBio, Inc.

NasdaqCM:LONA Stock Report

Market Cap: US$83.3m

LeonaBio Management

Management criteria checks 3/4

LeonaBio's CEO is Mark Litton, appointed in Oct 2021, has a tenure of 4.75 years. total yearly compensation is $1.42M, comprised of 43.9% salary and 56.1% bonuses, including company stock and options. directly owns 0.64% of the company’s shares, worth $531.26K. The average tenure of the management team and the board of directors is 2.9 years and 4.4 years respectively.

Key information

Mark Litton

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage43.90%
CEO tenure4.8yrs
CEO ownership0.6%
Management average tenure2.9yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

Analysis Article • Feb 16

Will Athira Pharma (NASDAQ:ATHA) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Nov 02

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Analysis Article • May 29

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Analysis Article • Jan 04

Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Seeking Alpha • Oct 17

Athira Alzheimer's drug trial gets monitoring panel nod to continue after efficacy analysis

Athira Pharma (NASDAQ:ATHA) said an independent data monitoring committee recommended to continue a phase 2/3 trial of fosgonimeton (ATH-1017) to treat patients with mild-to-moderate Alzheimer's disease (AD). The committee made the recommended after an interim efficacy and futility analysis of the study, dubbed LIFT-AD, the company added. In addition, the panel decided that, with the additional enrollment of fewer than 150 patients for a total enrollment of less than 300 people without background therapy (acetylcholinesterase inhibitors), the trial will be well powered for the main goal given the preliminary effect size seen, according to the company. The main goal of the trial is Global Statistical Test, a tool for measuring cognition and function. Athira noted that data from a phase 2 study called ACT-AD had showed a favorable safety profile and suggested positive effects on measures of cognition, function and neurodegeneration in patients taking fosgonimeton without background therapy. ATHA +2.49% to $3.29 premarket Oct. 17
Seeking Alpha • Aug 15

Athira Pharma GAAP EPS of -$0.65

Athira Pharma press release (NASDAQ:ATHA): Q2 GAAP EPS of -$0.65. Cash, cash equivalents and investments were $282.2 million as of June 30, 2022, compared with $319.7 million as of December 31, 2021.
Analysis Article • Aug 09

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Seeking Alpha • Jun 22

Athira Pharma: The Market Is Missing A Potential New Alzheimer's Drug

Athira Pharma has just read out first Phase 2 results in one of two Alzheimer’s trials. Its drug candidate ATH-1017 targets the HGF/MET pathway, a unique approach which has led to promising Phase 1 data. The readout shows efficacy in a subgroup, underlining validity of the proposed pathway and drug candidate ATH-1017, and I expected this would happen. The company's shares are falling severely on the primary endpoint miss. Simply stated, if the primary endpoint would have been cognition in the monotherapy group, then the results would have been seen as successful, which is why I believe there is potential to be a new Alzheimer's drug in the making here.
Analysis Article • May 08

Companies Like Athira Pharma (NASDAQ:ATHA) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Jan 11

We're Not Very Worried About Athira Pharma's (NASDAQ:ATHA) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Jun 29

Athira Pharma: What, Exactly, Did The CEO Do?

CEO Leen Kawas is on leave because she is pending review for allegations of scientific misconduct. The science in question relates to Athira's core work in Alzheimer's. How strongly they are related will determine Athira's future.
Analysis Article • May 24

We Think Athira Pharma (NASDAQ:ATHA) Can Afford To Drive Business Growth

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
Analysis Article • Feb 08

We're Hopeful That Athira Pharma (NASDAQ:ATHA) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Dec 18

Here's What Athira Pharma, Inc.'s (NASDAQ:ATHA) Shareholder Ownership Structure Looks Like

The big shareholder groups in Athira Pharma, Inc. ( NASDAQ:ATHA ) have power over the company. Institutions often own...

CEO Compensation Analysis

How has Mark Litton's remuneration changed compared to LeonaBio's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$129m

Dec 31 2025US$1mUS$625k

-US$106m

Sep 30 2025n/an/a

-US$38m

Jun 30 2025n/an/a

-US$60m

Mar 31 2025n/an/a

-US$80m

Dec 31 2024US$3mUS$625k

-US$97m

Sep 30 2024n/an/a

-US$109m

Jun 30 2024n/an/a

-US$113m

Mar 31 2024n/an/a

-US$116m

Dec 31 2023US$2mUS$585k

-US$118m

Sep 30 2023n/an/a

-US$121m

Jun 30 2023n/an/a

-US$108m

Mar 31 2023n/an/a

-US$102m

Dec 31 2022US$4mUS$543k

-US$96m

Sep 30 2022n/an/a

-US$82m

Jun 30 2022n/an/a

-US$77m

Mar 31 2022n/an/a

-US$67m

Dec 31 2021US$3mUS$450k

-US$55m

Sep 30 2021n/an/a

-US$46m

Jun 30 2021n/an/a

-US$39m

Mar 31 2021n/an/a

-US$27m

Dec 31 2020n/an/a

-US$20m

Sep 30 2020n/an/a

-US$13m

Jun 30 2020n/an/a

-US$6m

Mar 31 2020n/an/a

-US$6m

Dec 31 2019US$204kUS$12k

-US$5m

Compensation vs Market: Mark's total compensation ($USD1.42M) is above average for companies of similar size in the US market ($USD659.85K).

Compensation vs Earnings: Mark's compensation has been consistent with company performance over the past year.

CEO

Mark Litton (58 yo)

4.8yrs
Tenure
US$1,423,815
Compensation

Dr. Mark J. Litton, Ph D., MBA, serves as Director at Lumen Bioscience, Inc. since October 2020. He served as Chief Operating Officer of LeonaBio, Inc. (formerly known as Athira Pharma, Inc.) since July 20...

Leadership Team

NamePositionTenureCompensationOwnership
Mark Litton
President4.8yrsUS$1.42m0.64%
$ 531.3k
Mark Worthington
General Counsel5.1yrsUS$731.48k0.20%
$ 163.0k
Javier San Martin
Chief Medical Officer2.3yrsUS$810.14k0.17%
$ 140.9k
Robert Renninger
Chief Financial Officer1.8yrsno data0.17%
$ 140.6k
Kevin Church
Chief Scientific Officer3.5yrsUS$1.34m0.27%
$ 223.3k
Julie Rathbun
Head of Investor Relationsno datano datano data
Mark F. Kubik
Chief Business Officerless than a yearno datano data
2.9yrs
Average Tenure
59yo
Average Age

Experienced Management: LONA's management team is considered experienced (2.9 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark Litton
President4.8yrsUS$1.42m0.64%
$ 531.3k
Grant Pickering
Independent Director4.5yrsUS$50.16k0.027%
$ 22.9k
Kelly Romano
Independent Chairwoman of the Board5.6yrsUS$90.66k0.086%
$ 71.6k
Joseph Edelman
Independent Director6.2yrsUS$49.16k0%
$ 0
Hans Moebius
Member of Scientific Advisory Board4.1yrsUS$1.29mno data
Marwan Sabbagh
Member of Scientific Advisory Board4.1yrsno datano data
Barbara Kosacz
Independent Director5.3yrsUS$59.16k0%
$ 0
Pierre Tariot
Member of Scientific Advisory Board4.1yrsno datano data
Michael A. Panzara
Independent Director4.3yrsUS$59.16k0%
$ 0
James Johnson
Independent Director5.9yrsUS$70.16k0.0053%
$ 4.4k
John Olichney
Member of Scientific Advisory Board4.1yrsno datano data
Anton Porsteinsson
Member of Scientific Advisory Board4.1yrsno datano data
4.4yrs
Average Tenure
64yo
Average Age

Experienced Board: LONA's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 08:30
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LeonaBio, Inc. is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Esther Lannie HongBerenberg
Eric SchmidtCantor Fitzgerald & Co.
Jason ButlerCitizens JMP Securities, LLC